This article is more than 5 years old. Information may no longer be current.
Top stories in hematology/oncology: New leukemia subtypes discovered, guidelines on radiotherapy after prostatectomy updated
Click Here to Manage Email Alerts
Among the top stories in hematology/oncology last week were the identification of new leukemia subtypes that may lead to improved diagnosis and treatment and the updating of the clinical guideline on adjuvant and salvage radiotherapy after prostatectomy by the American Society for Radiation Oncology and the American Urological Association.
Other highlights included research that suggested patients who undergo complex cancer surgery at hospitals affiliated with top-ranked cancer centers have a significantly higher risk for mortality than patients who undergo such surgeries at the flagship institutions, a study that found patients with rectal cancer who were responsive to neoadjuvant therapy may forgo surgery and the FDA granting fast track designation to leronlimab for metastatic triple-negative breast cancer.
Discovery of new leukemia subtypes may lead to targeted therapies, better outcomes
Researchers at St. Jude Children’s Research Hospital identified eight new subtypes of B-cell acute lymphoblastic leukemia, an advance that they hope could lead to improved diagnosis and treatment of high-risk children and adults. Read more.
American Society for Radiation Oncology, American Urological Association update guideline on radiotherapy after prostatectomy
The American Society for Radiation Oncology and American Urological Association have updated their joint clinical guideline on adjuvant and salvage radiotherapy after prostatectomy to reflect new research findings. Read more.
Top-ranked cancer hospitals outperform affiliates in surgical safety, mortality risk
Patients who undergo complex cancer surgery at hospitals affiliated with top-ranked cancer centers have a significantly higher risk for mortality than patients who undergo such surgeries at the flagship institutions, according to research published in JAMA Network Open. Read more.
Patients with rectal cancer responsive to neoadjuvant therapy may forgo surgery
Nonoperative “watch-and-wait” management may be a viable strategy for certain patients with rectal cancer who demonstrate a complete clinical response to neoadjuvant therapy, according to study results published in Surgical Oncology. Read more.
FDA grants fast track designation to leronlimab for metastatic triple-negative breast cancer
The FDA granted fast track designation to leronlimab for use in combination with carboplatin for the treatment of patients with CCR5-positive metastatic triple-negative breast cancer. Read more.